Tab 1 — Pandemic Fundamentals
Inter-Pandemic Period Phase 1–2
No animal influenza viruses circulating in humans. New animal influenza subtypes detected but not in humans. Focus on surveillance, stockpiling, planning.
Alert Period Phase 3–5
Human infection with a novel subtype. Limited human-to-human transmission possible. Small clusters; virus not well adapted for sustained spread. Rapid risk assessment, emergency response planning.
Pandemic Period Phase 6
Sustained community-level transmission in multiple WHO regions. Full pandemic response: surge capacity, non-pharmaceutical interventions, vaccine roll-out.
Transition Period Post-peak
Pandemic activity declining globally. Gradual return to inter-pandemic activities; evaluation, recovery, updating of national pandemic plans.
Epidemic
Sudden increase in cases of disease above expected rate in a specific geographic area. Time-limited. Example: MERS-CoV hospital clusters in Riyadh.
Pandemic
Epidemic occurring worldwide, crossing international boundaries, usually affecting many people simultaneously. Requires sustained, widespread community transmission. Example: COVID-19 (2020–2022).
Endemic
Disease consistently present at baseline level in a population or geographic area. Predictable occurrence. Example: MERS-CoV circulating in dromedary camel populations in the Arabian Peninsula.
R0 — Basic Reproduction Number
Average number of secondary cases one infected person generates in a fully susceptible population with no interventions. A biological property of the pathogen-host pair.
Rt — Effective Reproduction Number
R0 adjusted for current immunity and interventions. Rt > 1: epidemic growing. Rt = 1: stable. Rt < 1: declining.
Herd Immunity Threshold
Formula: HIT = 1 − (1/R0). For measles (R0=15): HIT = 93%. For COVID-19 delta (R0=6): HIT = 83%. Below HIT, chains of transmission break naturally.
| Pathogen | Type | R0 (est.) | CFR | Transmission | GCC Relevance |
|---|---|---|---|---|---|
| Influenza H1N1 (2009) | Virus | 1.2–1.6 | <0.1% | Droplet/airborne | Hajj mass gathering risk; annual vaccination |
| Influenza H5N1 | Virus (avian) | <1 | ~60% | Zoonotic (poultry) | Potential pandemic threat; poultry workers at risk |
| SARS-CoV-1 (2003) | Coronavirus | 2–4 | ~10% | Droplet/contact/some airborne | GCC: no major spread; lessons for IPC protocols |
| MERS-CoV | Coronavirus | 0.4–0.9 | ~35% | Zoonotic + healthcare | ENDEMIC in Arabian Peninsula; camel reservoir; hospital clusters in Saudi Arabia, UAE, Qatar |
| COVID-19 (SARS-CoV-2) | Coronavirus | 2–15 (variant) | 0.1–3% | Airborne/droplet/contact | Major GCC healthcare crisis 2020–2022; ongoing vaccination programmes |
| Ebola (EVD) | Filovirus | 1.5–2.5 | 25–90% | Direct contact (body fluids) | Low endemic risk; high traveller screening priority at GCC airports |
| Mpox | Orthopoxvirus | 1.1–2.4 | <1% (clade II) | Close physical contact | Imported cases reported; GCC travel hubs monitor incoming cases |
MERS-CoV in the Arabian Peninsula
- Dromedary camels are the primary zoonotic reservoir
- High-risk exposures: camel farms, camel markets, consuming raw camel milk
- Healthcare-associated transmission: major contributor to case clusters (Saudi Arabia, South Korea 2015 linked to returning traveller)
- Strict contact + airborne precautions in any suspected case
- No licensed vaccine or specific antiviral approved as of 2025
Mass Gathering Risk — Hajj
- 2–3 million pilgrims annually from 180+ countries
- Mandatory vaccinations: meningococcal ACWY, seasonal influenza
- Respiratory infections amplified by crowding, heat stress, sleep deprivation
- Saudi MOH deploys field hospitals, surge teams, surveillance units during Hajj season
High International Travel Hub Status
- Dubai, Doha, Riyadh, Abu Dhabi: among world's busiest aviation hubs
- Rapid importation and exportation of novel pathogens
- Entry screening protocols mandatory during alert/pandemic phases
- IHR-compliant points of entry (PoE) at all major airports
GCC Unified Response Structures
- Saudi MOH: national command centre, field epidemiology programme
- UAE: National Emergency Crisis and Disasters Management Authority (NCEMA)
- Qatar: Supreme Committee for Crisis Management
- Cross-border data sharing protocols under GCC framework
Tab 2 — Infection Prevention & Control
Hand Hygiene — WHO 5 Moments
- Before touching a patient — prevents transmission TO patient
- Before a clean/aseptic procedure — prevents infection at the site
- After body fluid exposure risk — protects HCW and environment
- After touching a patient — protects HCW and environment
- After touching patient surroundings — even if patient not touched
Alcohol-based hand rub (ABHR) preferred. Soap and water when hands visibly soiled or after Clostridium difficile exposure.
Other Standard Precaution Elements
- PPE: Gloves when touching blood/body fluids; gown if splash risk; mask and eye protection for procedures
- Sharps safety: Never recap needles two-handed; use safety-engineered devices; sharps disposal containers at point of care
- Respiratory hygiene/cough etiquette: Mask symptomatic patients at point of entry; tissues; hand hygiene after
- Environmental cleaning: Routine cleaning of high-touch surfaces; dedicated equipment per patient
- Waste management: Segregation of clinical vs domestic waste; yellow bags for infectious waste
- Safe injection practices: One needle, one syringe, one patient
| Type | Route | PPE Required | Room | Examples |
|---|---|---|---|---|
| Contact | Direct or indirect contact with patient/environment | Gown + gloves (on entry to room); remove before leaving | Single room preferred; cohort if necessary | MRSA, C. diff, VRE, scabies, norovirus |
| Droplet | Large respiratory droplets (>5 µm); travel <1 metre | Surgical mask + eye protection within 1 m; gown + gloves if close contact | Single room; door may stay open; curtain acceptable | Influenza, pertussis, mumps, meningococcal meningitis, MERS-CoV (standard care) |
| Airborne | Small particle aerosols (<5 µm); travel long distances and remain suspended | FFP3/N95 respirator (fit-tested); gown + gloves + eye protection | Negative pressure isolation room −2.5 Pa, ≥12 ACH, HEPA, self-closing door | TB, measles, varicella, COVID-19 (AGP), MERS-CoV (AGP/suspected) |
- Perform hand hygiene (ABHR or soap & water)
- Gown — tie at neck, then waist; ensure full coverage
- FFP3/N95 respirator — position over nose and chin; fit-check (seal check); no gaps
- Eye protection — goggles or face shield; adjust for fit
- Gloves — pull over gown cuffs to ensure continuous coverage
- Gloves — peel off first (most contaminated); do not touch skin; discard
- Perform hand hygiene
- Gown — unfasten ties; peel away from body/arms rolling outward; discard
- Perform hand hygiene
- Eye protection — grasp by the clean headband/sides; avoid front; discard or place in decontamination container
- Respirator — remove by grasping bottom strap then top strap; do NOT touch front; discard
- Perform hand hygiene
High-Risk AGPs
- Endotracheal intubation
- Extubation
- Bronchoscopy
- Open suction of airway
- CPR (chest compressions + bag-mask ventilation)
Moderate-Risk AGPs
- High-flow nasal oxygen (HFNO) >6 L/min
- Non-invasive ventilation (BiPAP/CPAP)
- Nebuliser treatment
- Tracheostomy care/suctioning
- Airway oscillation (e.g., PEP devices)
AGP Room Requirements
- Pressure: −2.5 Pa (negative)
- Air changes: ≥12 ACH
- Filtration: HEPA for exhaust air
- Door: Self-closing; remain shut
- Antechamber: Preferred for donning/doffing
- Visitors: Restricted; full PPE required
When single rooms are insufficient, cohort nursing groups patients with the same confirmed pathogen together in one ward or zone.
Cohort Nursing Principles
- Confirmed cases only: Never cohort suspected with confirmed
- Dedicated staff: Assign nurses/HCWs to cohort zones; no cross-movement
- Separate equipment: Stethoscopes, BP cuffs, thermometers per cohort
- Clear zone demarcation: Red (contaminated), Yellow (transition), Green (clean)
- Negative pressure preferred but not always achievable in surge
Zone Organisation
- Red Zone: Patient care area — full PPE worn at all times
- Yellow Zone: Transition/antechamber — donning/doffing area
- Green Zone: Clean area — staff break room, admin; no PPE
- Waste moves RED → YELLOW → disposal only
- Staff move GREEN → YELLOW (don) → RED → YELLOW (doff) → GREEN
Tab 3 — COVID-19 & MERS-CoV Nursing Care
| Severity | Clinical Features | SpO2 | Care Setting |
|---|---|---|---|
| Mild | Fever, cough, sore throat, myalgia, malaise; no dyspnoea, no hypoxia | ≥95% on room air | Home isolation; telemedicine follow-up |
| Moderate | Pneumonia signs; RR >20; dyspnoea; infiltrates on CXR/CT without severe hypoxia | 90–94% on room air | Hospital admission; supplemental O2 <5 L/min |
| Severe | RR ≥30/min; SpO2 <90% on room air; signs of respiratory distress; ARDS criteria met | <90% on room air | HDU/ICU; high-flow O2, possible NIV |
| Critical | ARDS, sepsis, septic shock, multi-organ failure, need for mechanical ventilation | Requires ventilation | ICU; invasive mechanical ventilation; vasopressors |
NEWS2 Scoring in COVID-19
- Validated early warning score adapted for COVID-19 (scale 0–20)
- 0–4: Low risk — routine monitoring
- 5–6: Medium risk — 4-hourly monitoring; medical review
- ≥7: High risk — continuous monitoring; urgent senior review/ICU liaison
- SpO2 Scale 2 used for patients requiring supplemental O2 (chronic hypercapnic risk: use Scale 1)
- New confusion (ACVPU score) scores 3 points — highly significant
Awake Proning Protocol
- Cycle: 2 hours prone → 2 hours lateral (left) → 2 hours lateral (right) → 2 hours supine; repeat
- Target: 16 hours per day in prone position
- Use pillows under chest, pelvis, shins to relieve pressure
- Monitor: SpO2, tolerance, pressure injuries (face, chest, knees)
- Contraindications: Haemodynamic instability, altered consciousness, facial/thoracic injuries, recent sternotomy
Dexamethasone Protocol
- Dose: 6 mg once daily (oral or IV) for up to 10 days
- Indication: Requiring supplemental O2 or mechanical ventilation
- Evidence: RECOVERY trial — 36% reduction in mortality in ventilated patients
- Do NOT use in mild COVID-19 not requiring O2 — may worsen outcomes
- Monitor: hyperglycaemia, secondary infection, fluid retention
Anticoagulation
- Prophylactic LMWH: All hospitalised COVID-19 patients unless contraindicated (bleeding risk)
- Therapeutic anticoagulation: Confirmed DVT/PE; moderate-severe disease with raised D-dimer and clinical deterioration (per local protocol)
- Monitor: platelet count, renal function, signs of bleeding
Other Treatments (select regimens)
- Remdesivir: Moderate disease; early hospitalisation within 7 days of symptom onset
- Tocilizumab/Baricitinib: Severe/critical with elevated inflammatory markers
- High-flow nasal oxygen (HFNO): Before escalating to invasive ventilation; titrate to SpO2 92–96%
Long COVID Definition (WHO)
Symptoms occurring within 3 months of acute COVID-19 onset, lasting ≥2 months, not explained by an alternative diagnosis.
Common Symptoms
- Fatigue, post-exertional malaise (PEM)
- Cognitive impairment ("brain fog")
- Breathlessness, persistent cough
- Chest pain, palpitations
- Joint and muscle pain
- Anxiety, depression, sleep disturbance
Nursing Assessment
- 6-minute walk test (6MWT) — functional capacity
- Spirometry and pulse oximetry on exertion
- Cognitive screening tools (MoCA)
- Mental health screening (PHQ-9, GAD-7)
- Referral pathways: respiratory, cardiology, neuropsychology
MIS-C / MIS-A
Multisystem Inflammatory Syndrome in Children/Adults — rare but severe post-COVID complication. Features: fever, hyperinflammation, organ dysfunction, elevated CRP/ferritin/D-dimer. Requires paediatric critical care input.
Transmission & Reservoir
- Reservoir: Dromedary camels (Camelus dromedarius) — MERS-CoV highly prevalent
- Zoonotic transmission: Contact with camels, nasal discharge, raw camel milk, undercooked camel meat
- Human-to-human: Mainly nosocomial; limited sustained community spread
- R0 community: 0.4–0.9 (self-limiting without healthcare amplification)
- R0 healthcare setting: Can exceed 1 without strict IPC
Clinical Presentation
- Incubation: 2–14 days (median 5 days)
- Range: Asymptomatic → severe pneumonia → ARDS
- GI symptoms common: nausea, vomiting, diarrhoea
- Renal failure: a distinguishing feature vs COVID-19 and SARS
- High-risk groups: immunocompromised, diabetes (very common in GCC), chronic renal/lung disease
IPC in MERS-CoV
- Contact + Airborne precautions — from point of suspicion
- Negative pressure room; 12 ACH minimum; HEPA filtration
- FFP3/N95 for all staff entering room
- Strict doffing protocol with buddy system
- Limit staff entering room — designate lead nurse
- Avoid AGPs unless absolutely necessary; if needed: full airborne precautions
Treatment (Supportive)
- No approved specific antiviral for MERS-CoV as of 2025
- Supportive: oxygen therapy, mechanical ventilation for ARDS
- Experimental: convalescent plasma, interferon combinations (clinical trial settings)
- Corticosteroids: controversial; may delay viral clearance
GCC Hospital Clusters — Key Learning
- Large hospital cluster: Saudi Arabia 2014 — 255+ cases linked to one hospital
- South Korea 2015 cluster — traced to single traveller from GCC; 186 cases, 38 deaths
- Poor triage, overcrowding, delayed IPC = amplification
- Lessons: triage posters, universal masking, early isolation of fever + respiratory symptoms
Tab 4 — Surge Capacity & Crisis Standards of Care
Normal or moderately increased demand. Standard staffing ratios maintained. All services operational. Routine protocols followed.
Significant patient surge. Minor adaptations: postponing elective procedures, increasing staffing, repurposing spaces, reducing documentation burden.
System overwhelmed. Care provided may not meet usual standards. Triage decisions required. Ethical framework invoked for resource allocation.
Crisis Standards of Care is a formal declaration that a healthcare system cannot provide usual care due to overwhelming demand. It shifts ethical basis from individual-optimised care to population-level best outcomes.
CSC Decision Framework
- Conventional: Standard protocols; individual patient-centred decisions
- Contingency: Functionally equivalent care with adapted processes; maximise capacity
- Crisis: May not meet usual care standards; goal shifts to maximise lives saved across population
- Transition between levels requires institutional authority and ideally governmental declaration
- Documentation of CSC status is legally and ethically essential
Ventilator Allocation (Triage)
- Utilitarian principle: Maximum benefit for most people
- SOFA score or TISS score commonly used for ICU allocation in crisis
- Time-limited trials (e.g., 48–72 hours) then reassessment
- Exclusion criteria defined in advance (not at bedside): irreversible terminal illness, severe multi-organ failure
- Decisions made by triage team — NOT the bedside nurse alone
Palliative Care Escalation
- Integral to pandemic response — not a last resort
- Early goals-of-care conversations with all high-risk patients
- Comfort-focused care for those not receiving ICU interventions
- Nurse's role: advance care planning, symptom management, family communication
- Opioids, anxiolytics for dyspnoea; oral care; dignity in dying
Ethical Principles in Crisis
- Beneficence: Do good for the most patients possible
- Non-maleficence: Avoid futile interventions that deny others care
- Justice: Fair allocation criteria, free from bias (no allocation based on social worth or disability)
- Autonomy: Respect advance directives; meaningful consent where possible
- Nurses are patient advocates — escalate concerns about unfair triage
Converting Wards to ICU Capacity
- Step-down units first: HDU/step-down converted to ICU standard before general wards
- Portable ventilators and monitoring deployed to general ward bays
- Operating theatres converted to ICU — anaesthesia ventilators repurposed
- Elective surgery suspended to free theatre ICU capacity
- Minimum equipment per bed: ventilator, monitor, infusion pumps, suction
Training Non-ICU Nurses
- Compressed ICU orientation (typically 3–5 days surge training)
- Focus areas: ventilator basics, vasopressor titration, arterial line care, CRRT principles
- Buddy system: 1 experienced ICU nurse paired with 1–2 redeployed nurses
- Simulation-based rapid skills training preferred
- Scope of practice adjustments formally documented and legally covered
Surge Staffing Models
- Team nursing: Small teams with mixed skill levels; experienced nurse leads; tasks distributed by competency
- Task-based allocation: Specific tasks assigned to specific staff (e.g., one nurse manages all medications for zone)
- Floating pool: Hospital-wide float pool activated; flexibility between departments
- Military hospital activation in GCC: armed forces medical staff deployed to civilian hospitals
GCC Pandemic Response Structures
- Centralised MOH command: Single national command centre; daily ministerial updates
- Unified protocols: All hospitals follow identical national pandemic nursing protocols
- Military hospital activation: National Guard, Armed Forces hospitals activated in Saudi Arabia, UAE during COVID-19 peak
- Private sector integrated into national surge capacity planning
Signs of Burnout
- Emotional exhaustion, cynicism, depersonalisation
- Reduced sense of personal accomplishment
- Physical symptoms: insomnia, headaches, immune suppression
- Absenteeism, increased errors, intention to leave profession
- Assessed with Maslach Burnout Inventory (MBI)
Signs of Moral Injury
- Guilt, shame, sense of betrayal
- Intrusive thoughts about patient deaths
- Anger at institutional decisions
- Loss of meaning in clinical work
- PTSD-like symptoms (flashbacks, avoidance)
Institutional Support Structures
- Psychological First Aid (PFA): Peer support programmes; trained wellbeing champions on every ward
- Debriefing sessions: Structured hot and cold debriefs after critical incidents
- EAP access: 24/7 Employee Assistance Programme; confidential counselling
- Workload management: Maximum consecutive shift limits; mandatory breaks
- Leadership visibility: Senior nurses and managers present in the clinical area
- Recognition programmes: Acknowledgment of extraordinary effort without normalising exploitation
Tab 5 — Vaccination & Public Health
Cold Chain Management
- Temperature range: +2°C to +8°C for most inactivated/subunit vaccines; −70°C for mRNA (Pfizer/BioNTech)
- Continuous temperature monitoring with data loggers; never use a vaccine with temperature excursion before pharmacist/infection control review
- Transport in validated cold boxes with ice packs; never pack ice directly against vials
- Vaccines stored in middle shelves of dedicated vaccine fridge — never door shelves
- VVM (Vaccine Vial Monitor): Check inner square is lighter than outer circle; discard if inner square darker or equal
Anaphylaxis Preparedness
- Resuscitation equipment immediately available at every vaccination station
- Adrenaline (epinephrine) 1:1000 — 0.5 mg IM into anterolateral thigh (adult); may repeat after 5 minutes
- Observe all vaccinees: 15 minutes post-dose standard; 30 minutes for history of anaphylaxis
- Recognise anaphylaxis: urticaria, angioedema, bronchospasm, hypotension, tachycardia, vomiting within minutes of injection
- Call emergency team; lay flat with legs raised (unless respiratory compromise); give adrenaline; transfer to ED
Informed Consent Documentation
- Patient must receive verbal explanation and written information leaflet
- Document: vaccine name, batch number, site, dose, route, date, consent confirmation, observer
- Capacity to consent assessed; for minors: parent/guardian consent required; Gillick competency for teenagers
- In mass vaccination settings: pre-screened consent forms acceptable
AEFI Reporting (Adverse Events Following Immunisation)
- Classify: minor (local pain, fever), moderate (febrile seizure, severe local reaction), severe (anaphylaxis, hospitalisation, death)
- Report ALL serious AEFIs within 24 hours to national pharmacovigilance system
- GCC systems: Saudi FDA (SFDA), UAE Health Authority, QCDD (Qatar)
- WHO global AEFI reporting via VigiBase
- Document in patient record and vaccination register independently
Site Setup Principles
- Unidirectional patient flow: registration → screening → vaccination → observation → exit
- Minimum 15-minute observation area with seating; resus bay at end
- Signage in multiple languages (Arabic, English, Urdu, Tagalog for GCC)
- Digital or paper pre-registration to reduce queuing
- Dedicated lane for elderly, wheelchair users, staff
Throughput Optimisation
- Throughput formula: number of vaccinators × doses per hour per vaccinator
- Target: 5–6 minutes per person at vaccination station
- Bottleneck analysis: identify slowest station (usually registration or screening)
- Drive-through vaccination centres: highly effective for rapid throughput (used extensively in UAE, Saudi during COVID-19)
Documentation Systems
- National immunisation registry (e.g., Saudi SFDA vaccine tracker; UAE "Al Hosn" app)
- Every dose logged: time, vaccinator ID, batch number, site
- Paper backup mandatory if electronic systems fail
- End-of-day reconciliation: doses prepared vs administered vs wasted
Vaccine Wastage Reduction
- Open multi-dose vials only when appointment confirmed
- Pfizer/Moderna: use opened vials within 6 hours once reconstituted/punctured
- Record and report wastage per WHO protocol
- "Zero wastage" policy: seek additional recipients from waiting list before discarding opened vials
Key Definitions
- Index case: First identified case in an outbreak — may not be the primary case
- Primary case: First case who introduced pathogen to the group
- Close contact: Typically within 1 metre for ≥15 minutes without PPE (varies by pathogen)
- Quarantine: Separation of exposed individuals who are not (yet) ill — duration = maximum incubation period
- Isolation: Separation of confirmed or probable cases from well people
Contact Tracing Process
- Identify index case; establish symptom onset date
- Define infectious period: 48 hours before symptoms to isolation
- List all contacts within infectious period; classify as close vs casual
- Notify contacts; provide quarantine instructions; arrange testing
- Monitor quarantined contacts daily for symptom development
Outbreak Investigation Steps
- Verify the diagnosis — laboratory confirmation
- Establish a case definition — clinical + epidemiological criteria (suspected/probable/confirmed)
- Find cases — active case finding; line list all cases
- Describe outbreak — person (who?), place (where?), time (when?) → epidemic curve
- Formulate hypothesis — probable source and mode of transmission
- Test hypothesis — cohort or case-control study; environmental sampling
- Implement control measures — while investigation ongoing
- Communicate findings — MOH notification, WHO if IHR criteria met
Attack Rate Calculation
Attack Rate (%) = (Number of cases ÷ Population at risk) × 100
Used to compare risk across groups; guides source identification.
GCC Notifiable Disease Reporting
- All GCC countries have mandatory notifiable disease lists aligned with WHO IHR
- Immediate notification (within 24 hours): cholera, plague, yellow fever, smallpox, SARS, COVID-19, Ebola, MERS-CoV, Marburg, Lassa
- Weekly notification: tuberculosis, typhoid, hepatitis A/B, measles, meningococcal disease, malaria
- Nurse's role: report to infection control team; infection control reports to MOH
WHO IHR (International Health Regulations 2005)
- Legally binding international agreement — 196 States Parties
- PHEIC: Public Health Emergency of International Concern — highest WHO alert
- Countries must notify WHO within 24 hours of any potential PHEIC event
- IHR compliant capacities: surveillance, laboratory, response, communication, zoonoses, food safety, chemical, radiological
- GCC ports of entry must maintain IHR core capacities at all international airports and seaports
Tab 6 — GCC Context & Exam Preparation
Saudi Arabia — MERS-CoV Timeline
- 2012: First MERS-CoV case identified in Saudi Arabia (Dr. Ali Mohamed Zaki, Jeddah)
- 2014: Large hospital cluster in Jeddah — 255+ cases, exposed inadequate IPC systems
- 2015: South Korea outbreak traced to returning Saudi Arabia traveller — global IHR implications
- 2019: Saudi Arabia: 213 new cases; MOH launched national MERS-CoV preparedness plan
- Ongoing: MERS-CoV cases reported annually; dromedary camels remain primary reservoir
- Saudi SCFHS pandemic nursing exams include MERS-CoV scenarios
UAE COVID-19 Response
- First COVID-19 cases: January 2020
- Vaccination programme: World's highest per-capita vaccination rate (2021)
- Sinopharm (BBIBP-CorV): Primary vaccine; approved January 2021; two doses 21 days apart
- Pfizer-BioNTech (Comirnaty): Approved alongside Sinopharm; mRNA platform
- DHA and DOH (Abu Dhabi): separate licensing bodies; unified pandemic protocols
Qatar COVID-19 Response
- Rapid vaccination campaign: Pfizer primary; booster doses from mid-2021
- Hayat-Vax: Locally branded Sinopharm vaccine produced in collaboration with G42 Healthcare (Abu Dhabi); approved by NCBE Qatar
- Mass vaccination centres at Qatar Foundation, Hamad Medical City
- Ehteraz app: mandatory contact tracing and vaccination status app
Hajj Pandemic Preparedness
- Meningococcal ACWY vaccine: Mandatory for all Hajj pilgrims (quadrivalent MenACWY conjugate)
- Influenza vaccine: Strongly recommended; mandatory for many nationalities
- COVID-19 vaccination required during 2021–2023 Hajj seasons
- Heat + infection synergy: Heat stroke immunosuppression increases infection susceptibility; synergistic mortality risk in elderly pilgrims
- Saudi MOH: 25+ field hospitals, 400+ physicians, 1,200+ nurses deployed annually during Hajj
- Respiratory syndrome surveillance: daily reporting to WHO during Hajj season
DHA (Dubai)
- IPC standard precautions and PPE donning/doffing sequence
- WHO 5 moments of hand hygiene
- MERS-CoV: transmission routes, IPC requirements
- COVID-19 severity classification and NEWS2
- Anaphylaxis: recognition and adrenaline dosing
- AEFI reporting processes
DOH (Abu Dhabi)
- Airborne vs droplet vs contact precautions
- AGP identification and required precautions
- Pandemic phases and nursing response at each
- Crisis Standards of Care ethical framework
- Cold chain management
- Herd immunity threshold calculation
SCFHS (Saudi Arabia)
- MERS-CoV: camel exposure, hospital clusters, CFR
- Negative pressure room specifications
- Awake proning protocol steps
- Dexamethasone: dose, indication, monitoring
- Outbreak investigation methodology
- WHO IHR notifiable disease reporting
Click an option to reveal whether it is correct. A brief rationale is provided with each answer.
PPE Level Selector — Interactive Tool
Select a clinical scenario to display the exact PPE required, donning order, room type, and disposal instructions.